M Performance Standards for Antimicrobial. Susceptibility Testing. This document includes updated tables for the Clinical and. Laboratory Standards. The tables in CLSI document M,1 when used in conjunction with this standard, represent the most current information for drug selection. [DOWNLOAD] Clsi Guidelines M S23 PDF [BOOK]. Book file PDF easily for everyone and every device. You can download and read online.
|Published (Last):||2 July 2009|
|PDF File Size:||6.36 Mb|
|ePub File Size:||11.14 Mb|
|Price:||Free* [*Free Regsitration Required]|
K100 previous method produced most MIC results against S. All telavancin MIC QC values obtained by frozen-form panels prepared according to the previous and revised methods were within the ranges published in the MS23 and MS24 documents, respectively 38— The revised BMD method provides lower MIC results for telavancin, especially when tested against staphylococci and enterococci. Similar experiments were performed for telavancin, and similar results were obtained data on file; Theravance, Inc.
It is also important to mention that although this revised method provides lower MIC determinations for telavancin, the antimicrobial susceptibility profile remains similar to that established by using the previous BMD method 1213— Less-significant MIC decreases 1 to 2 log 2 dilution steps were observed when testing streptococci in broth supplemented with blood, which showed similar MIC 50 values for both methods.
Methicillin-resistant Staphylococcus aureus MRSA is a multi-drug resistant pathogen, s2 is responsible for increasing cases of serious diseases, including life-threatening diseases and nosocomial and community-acquired infections.
Coordination of scientific review of the draft manuscript by Theravance and partners was conducted by Suzanne Douthwaite, an employee of Envision Scientific Solutions, funded by Theravance. Footnotes Published ahead of print 14 July Advancing excellence in laboratory medicine for better healthcare worldwide. MS23 includes a dosage regimen for imipenem for Pseudomonas aeruginosa and new information for detection of inducible clindamycin resistance using the Cosi test or broth microdilution for Streptococcus pneumoniae.
Update on the telavancin activity tested against European staphylococcal clinical isolates This article has been cited by other articles in PMC. Initially, Gram-positive clinical strains collected during previous worldwide surveillance programs During the development of this revised method, previous telavancin MIC determinations obtained when P was added only at the latest step bacterial inoculation resulted in MIC values against S. Expanded recommendations for testing fluoroquinolones and salmonella, and elimination breakpoints for beta-lactamase, other than oxacillin cefoxitinpenicillin, and ceftaroline for staphylococci are included.
National Center for Biotechnology InformationU. In summary, these k100 results demonstrate that the previous BMD method adopted by CLSI use of DMSO as a solvent and diluent for panel preparation and addition of P to the broth ensures a proper assessment of the telavancin MIC determination, especially when tested against staphylococci and enterococci. The previous method generated results against all E. Telavancin is a lipoglycopeptide antibiotic with potent in vitro bactericidal activity when tested against Gram-positive bacteria, including methicillin-susceptible Staphylococcus aureus MSSAmethicillin-resistant S.
Updated Version of CLSI’s Best-Selling Standard-MSis Now Available – IFCC
In addition, P was incorporated into the test medium. This is secondary to the use of DMSO for panel production and the presence of P, which ensure the proper telavancin testing concentration and result in a more accurate MIC determination. As clssi observed with dalbavancin cpsi and oritavancin 5the data presented here, using a large collection of clinically relevant strains, shows that the revised J100 method containing the addition of P common to all three lipoglycopeptides provides lower MIC results than those obtained by the previous method, especially when tested against staphylococci and enterococci.
Initial studies using this revised method observed that the MIC 50 results for telavancin were 4- to 8-fold lower than those obtained by the previous applied method use of DMSO and water as solvent and diluent for panel preparation, respectively, and no P supplementation when tested against staphylococci and enterococci, but minimal differences were observed when testing streptococci data on file; JMI Laboratories.
Communications and Publications
Clinical and Laboratory Standards Institute. Work more efficiently by providing the latest recommendations for detecting emerging resistance in an easy-to-use format. In addition, the telavancin MIC results obtained with the revised method were compared with several candidate xlsi formulation panels. Class II special controls guidance document: Laboratory identification of Dlsi is crucial and essential both for initiation of appropriate antimicrobial therapies and for effective infection control strategies that are designed to limit the spread of MRSA.
MHB was supplemented with 2. The purpose of this study was to fully evaluate telavancin MIC results when using the revised BMD method compared with those obtained by the previous CLSI method when tested against a larger collection of clinically relevant strains. Several Sensititre dry-form broth microdilution panel candidate ss23 eight were manufactured and tested simultaneously with the previous and revised frozen-form panels. Moreover, earlier studies where the previous method was applied underestimated the in vitro drug potency.
In contrast, the disk diffusion methods with oxacillin and cefoxitin showed lower sensitivity MIC result variations and summary of essential agreement rates between dry-form broth microdilution formulation panel Sensititre and revised reference method for telavancin.
Food and Drug Administration. The results presented here also validate a commercial dry-form formulation panel, which can be used as an alternative method for telavancin susceptibility testing in the clinical microbiology setting, lcsi with adequate QC clai and interpretive breakpoints 389.
The Clinical and Laboratory Standards Institute CLSI is a not-for-profit membership organization that brings clai the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: